BEAM   $26.21  2.74% Market Open

Beam Therapeutics Inc
Last Events:

2023-08-05 Trend pattern changed from канал to сужающийся канал.

2023-08-03 Trend pattern changed from нисходящий треугольник to канал.

2023-08-02 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-08-02 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: entrance to the overbought zone.

2023-07-30 Signal in Stochastic changed from bearish reversal to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-07-30 Signal in MACD changed from bearish recovery to bearish weakening. Oscillator MACD is in the negative territory it's higher than the signal line and grows. These factors mean that the falling period is over. Last signal: main and signal line crossing.

2023-07-30 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: entrance to the overbought zone.

2023-07-29 Signal in MACD changed from bullish reversal to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.


Current temperature: 16.41
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 28.79
High with % probability:
Analyst Recommendations:
Number of estimates 13
Target Price Mean 50.54
Mean unverified/preliminary 50.54 / 50.54
Target Price Low / High 23.00 / 80.00
Median / STD DEV 56.00 / 20.89
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy ActivelyBuy
rsi Sell Buy ActivelyBuy
macd None None None
stoch None None None
ma20 None None ActivelyBuy
ma50 None None None
ma100 Buy Buy None
Candlestick PatternSept. 13, 2024 Deliberation Block Formation - consists of three black bodies with consecutively lower closes in a downtrend. The final day is a short black candlestick, a spinning top or a doji. Considered to be a bullish reversal pattern.
ISIN US07373V1052
ceo Mr. John M. Evans M.B.A.
Website https://beamtx.com
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.